HaimBio Selected for National Project 'IP-R&D Strategy Support Linked to Intellectual Property Rights' for 2 Consecutive Years

[Asia Economy Reporter Hyunseok Yoo] Haimbio, a bio company developing next-generation anticancer drugs, announced on the 21st that it was selected for the ‘2020 IP-R&D Strategy Support Project linked to Intellectual Property’ hosted by the Korean Intellectual Property Office and organized by the Korea Intellectual Property Strategy Development Institute, overcoming high competition. This is the second consecutive year of selection following last year’s first selection.

Haimbio, selected for this strategic support project, will receive support for patent protection and management of core proprietary technologies such as the anticancer drug candidate Starvanip, which is currently undergoing clinical trials, and five newly secured anticancer metabolism mechanism regulatory substances from last year, as well as guidance on R&D directions.

Starvanip, being developed by Haimbio, is an anticancer agent that effectively blocks ATP production within mitochondria, a regulator of cancer cell energy metabolism, making cancer cell survival impossible. Starvanip acts only on cancer cells without affecting normal cells, making it an anticancer drug with no side effects and safe from resistance.

After completing Tech Transfer of Starvanip from the Daegu-Gyeongbuk Medical Innovation Foundation New Drug Production Center (Director Kim Hoonjoo) and finishing the production of finished pharmaceuticals, Haimbio received IND approval for Phase 1 clinical trials from the Ministry of Food and Drug Safety in August last year. Phase 1 clinical trials have been underway since December last year at Yonsei Severance Hospital, targeting solid cancer patients who failed standard treatments.

The national project ‘IP R&D Strategy Support Project’ is a program where intellectual property strategy experts (PM) from the Korea Intellectual Property Strategy Development Institute and intellectual property analysis specialized institutions form teams to provide customized and close patent strategy establishment support to selected companies. The Korean Intellectual Property Office oversees the project and provides support such as response strategies for core patents for new technology and new business development, R&D directions, and strategies for creating excellent patents.

Kim Hongryul, CEO of Haimbio, stated, “Apart from domestic clinical trials of Starvanip, we participated in the ‘Biotech Showcase’ held last month in San Francisco, USA, where we held business meetings with numerous global pharmaceutical companies for global clinical trials and overseas business expansion.” He emphasized, “We will also attend ‘Bio Europe’ held in Paris, France, this coming March as a presenter to present our ongoing anticancer drug research and continue multifaceted commercialization discussions such as collaborative research and license-out with global pharmaceutical companies.”

This content was produced with the assistance of AI translation services.